Pd34-08 Immune Profiling of Testicular Germ Cell Tumors Reveals High Expression of Pd-l1 and Pd-1
Year: 2016
Type: article
Abstract: INTRODUCTION AND OBJECTIVES: Cisplatin is one of the most widely used and highly effective drug for the treatment of various solid tumors including germ cell tumors (GCTs).However, it has dosedependent side effects and among them, nephrotoxicity is the most well-known and clinically important toxicity.Nedaplatin is a secondgeneration platinum complex with reduced nephrotoxicity that exerts its antitumor activity against various cancers.Based on our previous report (Int J Clin Oncol 2009;14:436), nedaplatin exerted the equivalent antitumor effect as cisplatin with less toxicity in patients with relapsed or refractory GCTs.In this study, we investigated the efficacy and safety of a regimen consisting of paclitaxel and ifosfamide plus nedaplatin (TIN) for refractory or relapsed GCTs in patients with impaired renal function.METHODS: Among 68 patients who underwent TIN chemotherapy for refractory or relapsed GCTs, ten patients with study entry criterion of eGFR (estimated glemerular filtration rate) < 60 ml/min/ 1.73m 2 were assessed.The combination chemotherapy consisted of paclitaxel (210 mg/m 2 ) on day 1 and ifosfamide (1.2 g/m 2 ) on days 2-6 in combination with nedaplatin (100 mg/m 2 ) on day 2 every 3 weeks.RESULTS: Patients enrolled in this study exhibited eGFR with a median of 49.97 mg/ml/1.73m 2 (range 31.7-57.5).Paclitaxel, ifosfamide and nedaplatin therapy was carried out as second-line therapy in 4 patients, third-line in 4 and fourth-line or later in 2. Patients were pretreated with a median of 5.5 cycles of platinum-based chemotherapy (range 3-11 cycles) and administered with a median of 550mg/m2 of cisplatin.Patients received 2-6 cycles of the TIN combination chemotherapy and the overall response rate was 90%.No patient with chemotherapy-induced kidney dysfunction was observed.Furthermore, among the patients undergoing TIN therapy, there was no difference in the frequency of side effects between eGFR ?60 ml/min/1.73m 2 and eGFR <60 ml/min/1.73m 2 groups.CONCLUSIONS: Paclitaxel, ifosfamide and nedaplatin chemotherapy is considered to be one of the effective and safe regimens in GCTs patients with impaired renal function.
Source: The Journal of Urology
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2321899894